The Lipid Vector Technology (LVT) arose from extensive highly innovative research carried out over more than a decade at Norsk Hydro. Clavis Pharma has capitalised on this knowledge and technology by acquiring and further developing the intellectual property portfolio assembled throughout these years, including preclinical and clinical data, which enables the Company to bring a steady stream of compounds towards commercialisation.
Promising In vitro and In vivo data have been obtained on a large number of compounds covering a number of therapeutic areas.
Lipid Vector Technology consists of the chemical linking of specific lipids (Lipid Vectors) to selected pharmaceutical agents (parent drugs).
